Karin Jennbacken

This study compares the efficiency of cardiac-specific extracellular vesicles and lipid nanoparticles in delivering mRNA to the heart, finding that cardiac-specific vesicles are more effective with less liver accumulation.

This paper develops human mini-heart models of HFpEF, identifies SERCA2a downregulation, and demonstrates gene therapy efficacy, leading to a first-in-human clinical trial.

This study shows that modified mRNA encoding Myc and Cyclin T1 can induce cardiomyocyte proliferation and improve cardiac function after myocardial injury in mice.